Aditxt Inc. Portfolio Company CEO Recognized for Advancing Women's Health at 2025 STIMULATE Conference

Aditxt Inc. (NASDAQ: ADTX) has announced that Saundra Pelletier, CEO of Evofem Biosciences, its pending acquisition target, was awarded the Trailblazing Female Founders Award at the 2025 STIMULATE Conference in Nashville. This recognition underscores Pelletier's leadership in advancing women's sexual and reproductive health through Evofem's development of PHEXXI(R), a hormone-free contraceptive, and SOLOSEC(R), an oral treatment for bacterial vaginosis and trichomoniasis. The award coincides with Say Vagina Month, an initiative by Evofem aimed at fostering open discussions about vaginal health.

The acquisition of Evofem by Aditxt, expected to be completed in the second half of 2025, represents a significant step in Aditxt's strategy to expand its focus on women's health. The merger, under the July 2024 Amended and Restated Merger Agreement, is subject to several conditions, including shareholder approval and Aditxt's ability to raise approximately $17 million to fund the transaction. This includes $15.2 million required to satisfy Evofem's senior secured noteholder. Failure to meet these financial obligations could prevent the merger's completion.

Aditxt's innovative platform aims to democratize health innovations by collaborating with research institutions, industry partners, and shareholders. The proposed acquisition of Evofem is poised to introduce a new program dedicated to women's health, furthering Aditxt's mission to address significant societal challenges through collective progress. For more information on Aditxt's initiatives and updates, visit https://ibn.fm/ADTX.